Med schools failing on conflicts?

A new report from the linkurl:American Medical Student Association;http://www.amsa.org/ (AMSA) paints a gloomy picture of how US medical schools are failing to craft policies that keep the pharmaceutical industry at arm's length. The AMSA's linkurl:PharmFree Scorecard 2008,;http://www.amsascorecard.org/ released yesterday (June 3), surveyed 150 medical school's across the country, asking about the institutions' policies to limit linkurl:conflicts of interest;http://www.the-scientist.com/blog/di

Written byBob Grant
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share
A new report from the linkurl:American Medical Student Association;http://www.amsa.org/ (AMSA) paints a gloomy picture of how US medical schools are failing to craft policies that keep the pharmaceutical industry at arm's length. The AMSA's linkurl:PharmFree Scorecard 2008,;http://www.amsascorecard.org/ released yesterday (June 3), surveyed 150 medical school's across the country, asking about the institutions' policies to limit linkurl:conflicts of interest;http://www.the-scientist.com/blog/display/54300/ with pharmaceutical companies. According to the scorecard, only seven of the 150 medical schools received As, while some perennial physician training powerhouses - such as Harvard Medical School and New York University School of Medicine - received Fs. But are the nation's medical schools really failing at avoiding conflicts of interest? Perhaps not as badly as the AMSA's scorecard would have you believe. New York University, like 30 percent of the schools surveyed, simply didn't respond to the AMSA's request for policies. Harvard, on the other hand, may have gotten an F because its conflict of interest policies didn't mesh with the criteria laid out by the AMSA scorecard. Harvard's bad grade resulted from the fact that it reported to the AMSA that it had no conflict of interest policies that corresponded with the scorecard's specific criteria, according to the AMSA website. Harvard told the AMSA that a university-wide review of conflict of interest policies was underway, but the association could not ascertain that the review would specifically address the medical school and its unique potential for conflicts. The institutions topping the scorecard included the University of Pittsburg Medical Center, the University of California, San Francisco School of Medicine, and the Mount Sinai School of Medicine in New York. Though the scorecard suggests that most US medical schools are failing to prevent conflicts, the head of linkurl:The Prescription Project,;http://www.prescriptionproject.org/ which collaborated with the AMSA in producing the report, said that things can get better. "The schools that earned 'A' and 'B' scores are to be commended for setting a high bar and aggressively moving forward to ensure medical education, training and patient care is free of commercial bias," said executive director Robert Restuccia, in a Prescription Project linkurl:release.;http://www.prescriptionproject.org/newscenter/ "While we still have a long way to go, we are optimistic that the growing momentum for reform will change the landscape and there will be great improvement next year."
Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here
Add The Scientist as a preferred source on Google

Add The Scientist as a preferred Google source to see more of our trusted coverage.

Meet the Author

  • From 2017 to 2022, Bob Grant was Editor in Chief of The Scientist, where he started in 2007 as a Staff Writer. Before joining the team, he worked as a reporter at Audubon and earned a master’s degree in science journalism from New York University. In his previous life, he pursued a career in science, getting a bachelor’s degree in wildlife biology from Montana State University and a master’s degree in marine biology from the College of Charleston in South Carolina. Bob edited Reading Frames and other sections of the magazine.

    View Full Profile
Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Graphic of amino acid chains folded into proteins

Expi293™ PRO Expression System: Higher Yields Across a Wider Variety of Proteins

Thermo Fisher Logo